Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178895 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL25143 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178890 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL2182769 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL17746959 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178762 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178760 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178759 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178761 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178892 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-116622005-B | Polymer prodrug compound and preparation method thereof, and polymer prodrug micelle and preparation method thereof | 成都中医药大学 | 2025-02-14 | — | — | CN | disclosed |
| US-11952434-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-112851755-B | Linear lipopeptide compound and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-09-01 | — | — | CN | disclosed |
| CN-116622005-A | Polymer prodrug compound and preparation method thereof, and polymer prodrug micelle and preparation method thereof | 成都普康生物科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11623009-B2 | Bone fracture repair by targeting of agents that promote bone healing | PURDUE RESEARCH FOUNDATION (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230101323-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-30 | — | — | US | disclosed |
| US-6858591-B2 | Antibiotic AA 896 analogs | WYETH HOLDINGS CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-6803384-B2 | FOR THERAPY OF REPERFUSION INJURY | HOFFMANN-LA ROCHE INC. | 2004-10-12 | — | — | US | disclosed |
| WO-2004009134-A1 | PROCEDURES OF CELLULAR LABELLING WITH PARAMAGNETIC COMPLEXES FOR MRI APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2004-01-29 | — | — | WO | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | AMERICAN CYANAMID COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2002086139-A1 | ANTIBIOTIC AA 896 ANALOGS | WYETH HOLDINGS CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6331640-B1 | TREATMENT OF REPERFUSION INJURIES | HOFFMANN-LA ROCHE INC. | 2001-12-18 | — | — | US | disclosed |
| EP-0831922-A2 | IMPROVED PHARMACEUTICAL COMPOSITIONS FOR GENE THERAPY | Therexsys Limited (GB) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996041606-A2 | IMPROVED PHARMACEUTICAL COMPOSITIONS FOR GENE THERAPY | THEREXSYS LIMITED (GB) | 1996-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952434-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885HTT 4618/4885EPHX2 2816/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | KMT2A 4508/4885HTT 548/4885EPHX2 1777/4885 |
| US-20230101323-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | KMT2A 3513/4885HTT 4618/4885EPHX2 2816/4885 |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | KMT2A 1528/4885HTT 3611/4885EPHX2 3786/4885 |
| US-11623009-B2 | Bone fracture repair by targeting of agents that promote bone healing | CTSK, CTSG, MMP13 | KMT2A 4423/4885HTT 4869/4885EPHX2 1839/4885 |
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | UMPS, METTL3, FPR3 | KMT2A 3211/4885HTT 1134/4885EPHX2 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.